ASCO 20.06.2017

עדכונים מ ASCO 2017

להלן מספר מחקרים מעניינים אשר הוצגו בכנס ASCO האחרון

Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM)

A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC)

KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma

Mutation burden as a potential prognostic marker of melanoma progression and survival

Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment

Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses

PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study

Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression

Efficacy of combined hypofractionated radiotherapy and anti-PD-1 monotherapy in patients with melanoma

Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1)

Preliminary results from the international neoadjuvant melanoma consortium (INMC)

Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204

נושאים קשורים:  ASCO
מאמרים נוספים שיעניינו אותך
תגובות
 
האחריות הבלעדית לתוכנן של תגובות שיפורסמו על ידי משתמשי האתר, תחול על המפרסם ועליו בלבד. על המגיבים להימנע מלכלול בתגובות תוכן פוגעני או כל תוכן אחר, שיש בו משום פגיעה או הפרת זכויות של גורם כלשהו